Definitive treatment patterns and survival in stage II non-small cell lung cancer

被引:3
|
作者
Yan, Sherry X. [1 ]
Qureshi, Muhammad M. [2 ,3 ]
Suzuki, Kei [3 ,4 ]
Dyer, Michael [2 ,3 ]
Truong, Minh Tam [2 ,3 ]
Litle, Virginia [3 ,4 ]
Mak, Kimberley S. [2 ,3 ]
机构
[1] Boston Med Ctr, One Boston Med Ctr Pl, Boston, MA 02118 USA
[2] Boston Med Ctr, Dept Radiat Oncol, 830 Harrison Ave, Boston, MA 02118 USA
[3] Boston Univ, Sch Med, 72 E Concord St, Boston, MA 02118 USA
[4] Boston Med Ctr, Dept Surg, Div Thorac Surg, 830 Harrison Ave,3rd Floor, Boston, MA 02118 USA
关键词
Non-small cell lung cancer; Treatment patterns; Survival; Surgery; Radiotherapy; BODY RADIATION-THERAPY; PHASE-III; TNM CLASSIFICATION; UNITED-STATES; FRACTIONATED RADIOTHERAPY; TRIAL; CONCURRENT; MANAGEMENT; PROPOSALS; GROUPINGS;
D O I
10.1016/j.lungcan.2018.07.035
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: This study delineated definitive treatment patterns for Stage II non-small cell lung cancer (NSCLC) in the United States and evaluated survival by treatment approach. Materials and Methods: Patients with clinically-staged Stage II NSCLC treated with surgery-based therapy, chemoradiation, conventionally-fractionated radiation (CFR), or stereotactic body radiotherapy (SBRT) were identified using the National Cancer Database (NCDB). Median survival was estimated using Kaplan-Meier analysis. Crude and adjusted hazard ratios (HR) and 95% confidence intervals were computed using Cox regression modeling. Results: Between 2004-2012, 19,749 patients met study criteria: 13,382 (67.8%) underwent surgery-based treatment, 4,310 (21.8%) received chemoradiation, 1,606 (8.1%) received CFR, and 451 (2.3%) received SBRT. Surgery and SBRT utilization increased over time while CFR and chemoradiation decreased (all p < 0.002). Patients receiving radiation-based treatments were older, with more comorbidities, and higher T/N stage (all p < 0.0001). With median follow-up of 25.2 months, median survival was 51.6, 23.3, 15.4, and 23.7 months for surgery-based treatment, chemoradiation, CFR, and SBRT, respectively (p < 0.0001). On multivariate analysis, chemoradiation (HR 1.67 [1.59-1.75], p < 0.0001), CFR (HR 2.38 [2.22-2.55], p < 0.0001), and SBRT (HR 1.76 [1.53-2.01], p < 0.0001) were associated with decreased survival versus surgery-based treatment. CFR was associated with decreased survival versus chemoradiation (HR 1.52 [1.41-1.63], p < 0.0001) and SBRT (HR 1.39 [1.19-1.61], p < 0.0001). SBRT was associated with similar survival versus chemoradiation (HR 1.10 [0.95-1.27], p = 0.212). Conclusion: NCDB data demonstrate increasing use of surgery-based treatments and SBRT for Stage II NSCLC over time. Radiation-based therapies were associated with decreased survival compared to surgery. CFR was associated with decreased survival compared to chemoradiation and SBRT.
引用
收藏
页码:135 / 142
页数:8
相关论文
共 50 条
  • [31] PATTERNS OF RECURRENCE IN STAGE III NON-SMALL CELL LUNG CANCER TREATED WITH DEFINITIVE IMRT: EXPERIENCE AT AN ACADEMIC CANCER CENTRE
    Meem, Mahbuba
    Bezjak, Andrea
    Raman, Srinivas
    Li, Youquan
    Hope, Andrew
    Sun, Alexander
    RADIOTHERAPY AND ONCOLOGY, 2019, 139 : S80 - S80
  • [32] Stage II non small cell lung cancer: survival and treatment of 72 patients.
    Brunel-Crova, J
    Guibert, B
    Mulsant, P
    Souquet, PJ
    Geriniere, L
    Bombaron, P
    Bernard, JP
    REVUE DES MALADIES RESPIRATOIRES, 1997, 14 (06) : 457 - 463
  • [33] Comorbidity as a predictor of survival in veterans with stage I and II non-small cell lung cancer (NSCLC)
    Boholli, I.
    Hoover, D.
    Yang, W. M.
    Abanonu, C.
    Gonzalez, M.
    Kasimis, B.
    Chang, V. T.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [34] Changing Survival and Treatment Patterns in Patients Aged 80 or Older with Stage IV Non-Small Cell Lung Cancer (NSCLC)
    Anaka, M.
    Gibson, A.
    Dean, M.
    Elegbede, A.
    Petersen, L.
    Tudor, R.
    Sangha, R.
    Bebb, D. G.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S190 - S190
  • [35] Survival after radiation for stage I and II non-small cell lung cancer with positive margins
    Gulack, Brian C.
    Cox, Morgan L.
    Yang, Chi-Fu Jeffrey
    Speicher, Paul J.
    Kara, H. Volkan
    D'Amico, Thomas A.
    Berry, Mark F.
    Hartwig, Matthew G.
    JOURNAL OF SURGICAL RESEARCH, 2018, 223 : 94 - 101
  • [36] Treatment patterns and survival analysis in patients with unresectable stage III EGFR-mutated non-small cell lung cancer
    Liang, Huan-Wei
    Liu, Yang
    Pan, Xin-Bin
    AGING-US, 2024, 16 (01): : 857 - 871
  • [37] Probabilistic neural networks predict survival in stage I and II non-small cell lung cancer
    Marchevsky, AM
    Patel, S
    Stephenson, MA
    Gondo, M
    Brown, RW
    Younes, M
    Yi, ES
    Benedict, WP
    Anton, RC
    Cagle, PT
    LABORATORY INVESTIGATION, 1997, 76 (01) : 982 - 982
  • [38] Radiotherapy patterns of care for stage I and II non-small cell lung cancer in Sydney, Australia
    Nguyen, Andrew D.
    Wong, Wenchang
    Beydoun, Nadine
    Mohan, Sharanya
    Shafiq, Jesmin
    Vinod, Shalini K.
    JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY, 2019, 63 (01) : 131 - 141
  • [39] Treatment of Advanced-Stage Non-Small Cell Lung Cancer
    Gesthalter, Yaron
    Smyth, Robert
    Sullivan, Donald
    Kathuria, Hasmeena
    Sockrider, Marianna
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205 (05)
  • [40] Treatment of resectable stage IIIA non-small cell lung cancer
    Cardenal, Felipe
    Palmero, Ramon
    JOURNAL OF THORACIC DISEASE, 2017, 9 (01) : 13 - 15